 PhysicianForum --
June 2005
 In This Issue...
Biologic agents are key drivers
of growth in the markets for rheumatoid arthritis and psoriasis therapies. In
2003, biologic agents accounted for 92% of sales of disease-modifying therapies
to treat rheumatoid arthritis and 82% of sales of therapies to treat moderate
to severe psoriasis. Sales of these agents are driven primarily by their very
high cost, yet the high cost of these agents also limits their use.
Six biologic agents are currently
marketed for the treatment of RA and psoriasis. At present only one, the TNF?
inhibitor Enbrel (Amgen/Wyeth), is marketed for the treatment of both
indications. Enbrel is currently the market leader among biologic agents for
the treatment of both RA and psoriasis, and it appears likely to retain its
dominant position over the next five years.
The Decision Resources PhysicianForum
study "Impact of Biologics for Rheumatoid Arthritis and Psoriasis"
explores current opinion among specialists and HMO pharmacy directors regarding
these agents. We surveyed 70 rheumatologists, 70 dermatologists, and 20 HMO
pharmacy/medical directors to assess their views on this issue. This study
investigates the following:
- The current role of biologic agents in the treatment of
rheumatoid arthritis and psoriasis.
- Factors that shape rheumatologists' and
dermatologists' selection of biologic agents.
- HMO pharmacy director positions on currently available biologic
therapies; formulary placement issues, and cost control measures imposed by
HMOs.
- Physician opinion regarding the safety, convenience, and cost of
biologic therapy.
|
